Fig. 5From: 18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma∆TTL and ∆ADC values in therapy and control group. Note the significant suppression of tumor glucose metabolism (a) as well as the significant increase of tumor diffusivity under therapy (b)Back to article page